Project Grant R21AI201881
Award Date 8/3/26
Completion Date 7/31/28
Dollars Obligated $194K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Duke University $684,405 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop mucosal immunotherapies targeting recurrent urinary tract infections and inflammatory bowel disease. The funded research advances immunomodulation via self-assembled peptides (ISAP), a platform using modular supramolecular polypeptide nanomaterials designed to elicit neutralizing antibody responses against...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $427,313 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate tertiary lymphoid structures in eosinophilic chronic rhinosinusitis with nasal polyps. The research examines the mechanisms of type 2 inflammation in this recalcitrant disease and the basis of disease recurrence following discontinuation of dupilumab therapy. The central hypothesis...
- The National Institute of Allergy and Infectious Diseases awarded $600,000 to Zylo Therapeutics, Inc. on September 12, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and optimize a nitric oxide-releasing microparticle formulation for topical treatment of chronic rhinosinusitis. Chronic rhinosinusitis, characterized by persistent inflammation and infection of the nasal cavity and paranasal sinuses, affects approximately 13 million U.S. adults....
- The National Institute of Allergy and Infectious Diseases awarded Alveolus Bio, Inc. $301,768 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop RSB11, a Lactobacillus-based nasal spray therapeutic for chronic rhinosinusitis. RSB11 employs advanced particle engineering and spray drying technologies to optimize nasal delivery and bacterial viability. The award funds two research aims. Aim 1 involves comprehensive in vitro studies using...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $240,000 on July 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the pathogenic role of the OX40/OX40 ligand axis in chronic rhinosinusitis. The research tests the hypothesis that OX40/OX40L signaling drives pathogenic inflammation in chronic rhinosinusitis (CRS), a heterogeneous upper airway disease affecting up to 12 percent of Americans and prompting...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $237,831 on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study MESH1's regulation of RNA sensing through nucleotide metabolism. The research investigates how the cytosolic enzyme MESH1 regulates nucleotide metabolism and immune responses to aberrant RNA. The work addresses how MESH1 functions as a phosphatase for 3-phosphoadenosine 5-phosphate (PAP), a byproduct of...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $530,480 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop intravenously administered acetalated dextran microparticles for treating multiple sclerosis. The recipient will conduct basic and translational research on biopolymeric acetalated dextran microparticles designed to target B cells in vivo and induce antigen-specific...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $756,936 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop broadly protective medical countermeasures against merbecovirus and sarbecovirus through nanoparticle immunogen design. The research aims to elicit broadly neutralizing antibodies targeting conserved viral epitopes on the receptor binding domain and stem helix of coronavirus spike proteins. Preliminary...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $444,125 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to accelerate T cell immune reconstitution following cultured thymus tissue implantation (CTTI). The research addresses the urgent clinical need to speed immune recovery after thymus transplantation, which currently risks early post-transplant deaths from infection before immune reconstitution occurs. Duke's prior...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $533,926 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the functional contributions of neonatal-origin CD4 T cells to adult immunity and tissue function. Duke will develop and leverage a novel timestamping system to track T cells originating during early life as they persist into adulthood, characterizing their breadth of innate responsiveness during...